Aclaris Therapeutics, Inc. (ACRS): restructuring charge — Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024

Aclaris Therapeutics, Inc.

Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.
ATI-1777 Phase 2a results published in JID Innovations; Phase 2b topline data expected January 2024.
ATI-450 (zunsemetinib) repurposed for pancreatic cancer and metastatic breast cancer in collaboration with Washington University.
ATI-2138 (ITK/JAK3) indication reassessed due to competitive landscape; guidance in early 2024.
Company accelerating discovery programs from KINect platform to generate IND applications near term.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Aclaris Therapeutics, Inc. announced a restructuring with charges of totaling approximately $3.1 million (approximately 46%).

Type: restructuring
Charge: totaling approximately $3.1 million
Headcount: approximately 46%

Exact text from the filing

order to streamline operations, reduce costs and preserve capital. As a result of the reduction in force, the Company expects to incur a one-time charge totaling approximately $3.1 million in connection with one-time employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending December 31,

View on SEC.gov

Browse all restructurings & charges →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019911

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.